Evidence map›Paper›PMID 40046049›Full record

ArticleFrontiers in immunology2025

Measles vaccination in lung transplant candidates.

Мikhail P Kostinov, Valentina B Polishchuk, Аleksey А Ryzhov, Pavel I Zhuravlev, Natalia A Karchevskaya, Evgeniy A Tarabrin, Irina L Solovieva, Alexander P Cherdantsev, Izabella A Khrapunova, Elena P Foshina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Мikhail P KostinovLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
Valentina B PolishchukLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
Аleksey А RyzhovLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
Pavel I ZhuravlevDepartment of Epidemiology and Modern Vaccination Technology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Natalia A KarchevskayaDepartment of Thoracic Surgery, N. V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russia.
Evgeniy A TarabrinDepartment of Hospital Surgery, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Irina L SolovievaDepartment of Pediatrics, Ulyanovsk State University, Ulyanovsk, Russia.
Alexander P CherdantsevDepartment of Pediatrics, Ulyanovsk State University, Ulyanovsk, Russia.
Izabella A KhrapunovaDepartment of Epidemiology and Modern Vaccination Technology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Elena P FoshinaLaboratory of Immunological Research Methods, I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence of measles is now increasing. Measles is especially dangerous for high-risk individuals, including lung transplant candidates with severe progressive bronchopulmonary disorders. Objective: The objective of this study was to investigate how vaccine-induced immunity is developed in lung transplant candidates seronegative for measles. In order to study vaccine-induced measles immunity, the study subjects were divided in two groups. The main group consisted of 22 patients (11 males and 11 females) with severe bronchopulmonary disorders, aged 19 to 58. The control group was made up of healthcare providers who were matched with respect to age and gender to the patients in the main group. All study subjects were given a single dose of measles vaccine. Levels of anti-measles IgG antibodies (Ab) were measured by enzyme-linked immunosorbent assay (ELISA) using the VectoMeasles-IgG kit (Russia). Results: One month after vaccination, both study groups showed a statistically significant increase in anti-measles IgG Ab compared to baseline levels. In the main group, vaccine-induced Ab levels were significantly lower than in the control group (0.41 [0.098; 1.75] IU/mL Conclusion: Administration of a single dose of measles vaccine to seronegative lung transplant candidates with severe progressive bronchopulmonary disorders was safe and resulted in protective levels of antibodies in 73% of patients. One year after vaccination, anti-measles Ab were detected in 36% of the patients, which suggested that a single dose failed to induce a robust immune response in this patient population.

Indexed as

Lung TransplantationMeaslesMeasles VaccineMeasles virusAdultAntibodies, ViralFemaleHumansImmunoglobulin GMaleMiddle AgedVaccinationYoung AdultAntibodies, ViralImmunoglobulin GMeasles Vaccinebronchopulmonary disorderslung transplantmeaslesvaccinationvaccine induced measles immunity

Identifiers

PMID40046049
PMCPMC11880224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.